These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6192998)

  • 1. The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion.
    Lindblad B; Abisch E; Bergqvist D
    Eur J Clin Pharmacol; 1983; 24(6):813-8. PubMed ID: 6192998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination.
    Schran HF; Bitz DW; DiSerio FJ; Hirsh J
    Thromb Res; 1983 Jul; 31(1):51-67. PubMed ID: 6612697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion.
    Kanto J; Allonen H; Kleimola T; Mäntylä R
    Acta Pharmacol Toxicol (Copenh); 1980 Apr; 46(4):241-4. PubMed ID: 7368942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
    Müller-Schweinitzer E; Rosenthaler J
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):686-93. PubMed ID: 2442535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of dihydroergotamine and triacetyloleandomycin in the minipig.
    Martinet M; Kiechel JR
    Eur J Drug Metab Pharmacokinet; 1983; 8(3):261-7. PubMed ID: 6606577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans.
    Schran HF; Tse FL
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):1-4. PubMed ID: 3988387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits.
    Tse FL; Jaffe JM
    Eur J Drug Metab Pharmacokinet; 1984; 9(1):65-71. PubMed ID: 6714270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of dihydroergotamine (DHE) in conscious beagle dogs.
    Müller-Schweinitzer E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):162-5. PubMed ID: 2459013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data.
    de Hoon JN; Poppe KA; Thijssen HH; Struijker-Boudier HA; Van Bortel LM
    Br J Clin Pharmacol; 2001 Jul; 52(1):45-51. PubMed ID: 11453889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does dihydroergotamine potentiate the thromboprophylactic effect of dextran 70? A controlled prospective study in general and hip surgery.
    Bergqvist D; Lindblad B; Ljungström KG; Persson NH; Hallböök T
    Br J Surg; 1984 Jul; 71(7):516-21. PubMed ID: 6203596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection.
    Kanto J; Allonen H; Koski K; Koulu M; Lammintausta R; Mäntylä R; Kleimola T; Siirtola T
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):127-30. PubMed ID: 7228454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of dihydroergotamine in man.
    Little PJ; Jennings GL; Skews H; Bobik A
    Br J Clin Pharmacol; 1982 Jun; 13(6):785-90. PubMed ID: 7093108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally.
    Couet W; Mathieu HP; Fourtillan JB
    Fundam Clin Pharmacol; 1991; 5(1):47-52. PubMed ID: 2066050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine.
    Beermann B; Lahnborg G
    Thromb Haemost; 1981 Feb; 45(1):24-6. PubMed ID: 7245123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.
    de Marées H; Welzel D; de Marées A; Klotz U; Tiedjen KU; Knaup G
    Eur J Clin Pharmacol; 1986; 30(6):685-9. PubMed ID: 3533566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine.
    Baumgartner A; Jacot N; Moser G; Krähenbühl B
    Vasa; 1989; 18(2):152-6. PubMed ID: 2545054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Perispinal anesthesia and subcutaneous administration of low-dose heparin-dihydergot for prevention of thromboembolism].
    Allemann BH; Gerber H; Gruber UF
    Anaesthesist; 1983 Feb; 32(2):80-3. PubMed ID: 6189414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.
    Aellig WH; Rosenthaler J
    Eur J Clin Pharmacol; 1986; 30(5):581-4. PubMed ID: 3758146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects.
    Wyss PA; Rosenthaler J; Nüesch E; Aellig WH
    Eur J Clin Pharmacol; 1991; 41(6):597-602. PubMed ID: 1815973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.